Key recent performance for Savara stock

Savara (SVRA) has drawn attention after a mixed stretch for the stock, with a modest gain over the past week and month contrasted by a decline year to date and a very large 1 year total return.

Recent trading has been relatively steady, with a modest positive 7 day share price return and a decline year to date, set against a very large 1 year total shareholder return that reflects changing expectations around Savara’s rare respiratory disease pipeline and risk profile.

If you are comparing Savara with other healthcare and biotech ideas, this can be a good moment to broaden your watchlist and scan 40 healthcare AI stocks

With Savara now valued at about US$1.3b and a 1 year total return that is very large, investors are left with a simple question: is the stock still underappreciated, or is the market already pricing in future growth?

Preferred Price-to-Book Multiple of 7.6x: Is it justified?

On P/B, Savara trades at 7.6x, which screens as expensive next to both its direct peers and the broader US Biotechs industry at the latest close of $5.30.

P/B compares a company’s market value with its net assets. It is often used for clinical stage biopharma stocks that have limited or no current revenue and are still loss making. A higher P/B can indicate the market is assigning more value to the future pipeline, management execution and balance sheet strength than the present day book value suggests.

For Savara, the signals are mixed. The company currently reports no revenue and a net loss of $129.48m, yet forecasts point to faster revenue growth than both the wider US market and the Biotechs industry, and to a shift into profitability within the next 3 years. That combination can help explain why the stock trades at a premium multiple despite unprofitable current financials and a negative return on equity.

Against sector benchmarks, the gap is clear. Savara’s 7.6x P/B is well above its peer average of 4.1x, and even further ahead of the US Biotechs industry average of 2.4x. This suggests investors are currently willing to pay a materially higher price than is typical in the space for each dollar of book value.

Result: Price-to-book of 7.6x (OVERVALUED).

However, investors still need to watch for clinical trial setbacks around molgramostim and ongoing losses of US$129.482m, which could pressure sentiment on the stock.

Next Steps

Curious how bullish and cautious the overall picture on Savara really is? Take a close look at the data, move quickly if needed, and weigh both the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If Savara is on your radar, do not stop there. Use this moment to line up a few more stocks that fit your style before the crowd catches on.

• Target higher quality opportunities by scanning 47 high quality undervalued stocks that combine strong fundamentals with prices the market has not fully appreciated yet.
• Strengthen your income stream by reviewing 10 dividend fortresses built around companies with yields above 5% and a focus on stability.
• Sleep easier at night by checking 65 resilient stocks with low risk scores designed to highlight stocks with more resilient risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.